Zeev's Turnips Patch-No Politics (ZEEV)

[Pay_tience]

AOBO..3.78..is a profitable china biotechnology company.....

here is the chart and it looks like it's ready to turn up. Moneyflow has started to increase here:

http://stockcharts.com/def/servlet/SC.web?c=AOBO,uu[m,a]daclyyay[pb50!b200][vc60][iUe12,26,9!La12,26...

Here is AOBO's last quarterly report:

Fast Growing Chinese Biotech Reports 92 Percent Jump in Nine-Month Revenues


HONG KONG, Nov 17, 2003 /PRNewswire-FirstCall via Comtex/ -- American Oriental Bioengineering Inc. ( OTC:AOBO), a leading Chinese biotechnology company, today reported record results for the nine months ended September 30, 2003, reflecting increased demand for the Company's biotechnology, medical and soybean protein peptide products and the company's successful expansion of its market share in China.
Revenue for the nine months ended September 30, 2003 increased 92% to $14.8 million, compared to $7.7 million in the same period a year ago, while revenue for the three months ended September 30, 2003 increased 86% to $5.4 million compared to $2.9 million in the year ago period. The record results reflect a significant increase in demand for the Company's biotechnology, medical and soybean protein peptide products, primarily due to increased consumer usage of the Company's soybean-based nutraceuticals products.

Net income increased 320% to $3.7 million for the nine months ended September 30, 2003, compared to $883,692 in the same period a year ago, while net income for the three months ended September 30, 2003 increased nearly five-fold to $1.2 million from $273,263 in the year ago period. Net income on a per share basis was $0.13 for the first nine months of 2003, compared to $0.08 per share in the year ago period. Net income for the three months ended September 30, 2003 was $0.04 compared to $0.03 in the year ago period.

As of September 30, 2003 American Oriental Bioengineering had a cash balance of $4.3 million and a working capital surplus of $8.1 million. This compares with a cash balance of $2.8 million and a working capital surplus of $3.5 million in the year ago period.

Shujun Liu, Chief Executive Officer of American Oriental Bioengineering, said, "We continue to achieve record growth in our core biotechnology revenues, while improving our profitability and strengthening our balance sheet. We are also pleased with the ongoing progress we are making in operations area. Our existing manufacturing capacity will be dramatically expanded by an additional 2 million tons of soybean per year, once our new 5 million square foot, state-of-the-art technology center is constructed and fully online. Overall, we continue to focus on capturing increased market share of the fast growing Chinese biotechnology market and expanding into overseas markets, while making certain our expenses are aligned with our current business plan."

"As we look ahead to the current fourth quarter, we are very optimistic about our prospects. Demand continues to accelerate and American Oriental Bioengineering has the financial backing, medical research expertise, and proven management team needed to execute on our growth plan. Overall, we expect to achieve record revenue and net profit growth for the full year 2003."

"Finally, we are excited about preparations to launch a series of initiatives intended to update the financial and investor community on our programs and latest successes. We believe there is a significant opportunity to raise awareness among investors and to increase value for our stockholders. Our management team is focused on enhancing our communications efforts with current and potential investors and we are taking the necessary steps to achieve this objective. All indications suggest continuing momentum in our operations, as revenues are up, costs are down, net income is increasing, and our balance sheet remains healthy, giving us confidence in our prospects."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. ( OTC:AOBO) is a leading Chinese biotechnology company that uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. For more information visit bioaobo .